On February 14, 2025, Ronald Hunt, Chairman and director of the Company, notified the Company of his resignation as Chairman and director of the Company, effective immediately.
Key facts
Extracted from this filing and checked against the source text.
Iterum Therapeutics plc received a nasdaq deficiency notice notice regarding audit committee (rules 5605(c)(2)(A)).
Exchange
nasdaq
Notice
deficiency notice
Deficiency
audit committee
Rules
5605(c)(2)(A)
Exact text from the filing
February 14, 2025, Iterum Therapeutics plc (the “Company”), notified the Nasdaq Stock Market LLC (“Nasdaq”) that the Company will not be in compliance with the audit committee requirement under Nasdaq Listing Rule 5605(c
Iterum Therapeutics plc received a nasdaq noncompliance notice notice regarding audit committee (rules 5605(c)(2)(A)).
Exchange
nasdaq
Notice
noncompliance notice
Deficiency
audit committee
Rules
5605(c)(2)(A)
Exact text from the filing
February 14, 2025, Iterum Therapeutics plc (the “Company”), notified the Nasdaq Stock Market LLC (“Nasdaq”) that the Company will not be in compliance with the audit committee requirement under Nasdaq Listing Rule 5605(c)(2)(A) as of February 14, 2025, solely due to a vacancy on the audit committee (the “Audit Committee”) of the Company’s Board of Directors (the “Board”) resulting from Ronald Hunt’s resignation from the Board as disclosed in
Ronald Hunt resigned as Chairman and director at Iterum Therapeutics plc.
Action
resigned
Role
Chairman and director
Exact text from the filing
On February 14, 2025, Ronald Hunt, Chairman and director of the Company, notified the Company of his resignation as Chairman and director of the Company, effective immediately.
This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice.
See methodology for how this pipeline works.